Cidara Therapeutics, Inc. (CDTX)
Largest Insider Buys in Sector
CDTX Stock Price History Chart
CDTX Stock Performance
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its …
Insider Activity of Cidara Therapeutics, Inc.
Over the last 12 months, insiders at Cidara Therapeutics, Inc. have bought $105,680 and sold $75,650 worth of Cidara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cidara Therapeutics, Inc. have bought $207,124 and sold $55,479 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Stein Jeffrey (President & CEO) — $105,680.
The last purchase of 8,000 shares for transaction amount of $105,680 was made by Stein Jeffrey (President & CEO) on 2024‑06‑07.
List of Insider Buy and Sell Transactions, Cidara Therapeutics, Inc.
| 2024-09-11 | Sale | Chief Medical Officer | 924 0.0128% | $11.64 | $10,752 | +2.60% | ||
| 2024-09-11 | Sale | CHIEF SCIENTIFIC OFFICER | 909 0.0126% | $11.64 | $10,580 | +2.60% | ||
| 2024-06-07 | President & CEO | 8,000 0.1804% | $13.21 | $105,680 | -7.75% | |||
| 2024-03-11 | Sale | Chief Medical Officer | 20,662 0.0231% | $0.67 | $13,839 | -4.43% | ||
| 2024-03-11 | Sale | CHIEF SCIENTIFIC OFFICER | 21,029 0.0235% | $0.67 | $14,085 | -4.43% | ||
| 2024-03-11 | Sale | CFO & CBO | 18,931 0.0212% | $0.67 | $12,680 | -4.43% | ||
| 2024-03-11 | Sale | COO & CLO | 20,473 0.0229% | $0.67 | $13,713 | -4.43% | ||
| 2023-09-11 | Sale | Chief Medical Officer | 18,793 0.0205% | $0.95 | $17,810 | -26.20% | ||
| 2023-09-11 | Sale | CHIEF SCIENTIFIC OFFICER | 18,469 0.0202% | $0.95 | $17,509 | -26.20% | ||
| 2023-08-14 | CHIEF SCIENTIFIC OFFICER | 10,000 0.0118% | $0.97 | $9,700 | -20.54% | |||
| 2023-08-08 | President & CEO | 50,000 0.0566% | $0.96 | $47,885 | -22.05% | |||
| 2023-03-27 | President & CEO | 50,000 0.0653% | $1.04 | $51,855 | -9.78% | |||
| 2023-03-13 | Sale | Chief Medical Officer | 7,203 0.0081% | $1.53 | $11,021 | -45.66% | ||
| 2023-03-13 | Sale | CHIEF SCIENTIFIC OFFICER | 7,562 0.0085% | $1.53 | $11,570 | -45.66% | ||
| 2023-03-13 | Sale | CFO & CBO | 6,648 0.0075% | $1.53 | $10,171 | -45.66% | ||
| 2023-03-13 | Sale | COO & CLO | 4,329 0.0049% | $1.53 | $6,623 | -45.66% | ||
| 2023-01-12 | Sale | CHIEF SCIENTIFIC OFFICER | 11,814 0.015% | $1.20 | $14,177 | -13.33% | ||
| 2022-09-19 | Sale | CFO & CBO | 15,642 0.0226% | $0.77 | $12,035 | +38.16% | ||
| 2022-09-12 | Sale | Chief Medical Officer | 18,478 0.0264% | $0.68 | $12,656 | +51.03% | ||
| 2022-09-12 | Sale | Chief Operating Officer | 16,199 0.0232% | $0.68 | $11,095 | +51.03% |
Insider Historical Profitability
| Shah Preetam | CFO & CBO | 227210 3.2244% | $18.75 | 1 | 3 | <0.0001% |
| Stein Jeffrey | President & CEO | 24580 0.3488% | $18.75 | 16 | 0 | <0.0001% |
| Sandison Taylor | Chief Medical Officer | 23067 0.3273% | $18.75 | 2 | 5 | +18.64% |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER | 17788 0.2524% | $18.75 | 1 | 7 | |
| BIOTECH TARGET N V | 10 percent owner | 2295272 32.5726% | $18.75 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $6.31B | 150.41 | 6.86M | 0% | +$0 | 46.21 | |
| The Vanguard Group | $3.08B | 73.36 | 3.35M | 0% | +$0 | 0.06 | |
| Renaissance Technologies | $2.35M | 56.01 | 2.55M | +41.77% | +$692,701.18 | <0.01 | |
| Alethea Capital Management LLC | $1.47B | 35.04 | 1.6M | -1.79% | -$26.84M | 92.4 | |
| Point72 Asset Management | $1.15B | 27.4 | 1.25M | 0% | +$0 | 1.68 |